
Singapore · Biotechnology
Cerecin is a healthcare company that develops a novel evidence-based therapeutics and products that aim to help people.
PrivateFor profit
Set against 55 Biotechnology companies in Singapore. The ring marks the typical peer.
Across all 5.9M companies: larger than 33% of those with a size listed; older than 40% of those with a founding year; website ranked #13,122,906 in the world, about 78 visits a month. 37 people list it on LinkedIn, and 6,008 follow it.
Cerecin is a global healthcare company with more than 20 years of innovation and leadership in brain health. At Cerecin we think differently. We develop novel evidence-based solutions that help people; pharmaceuticals, medical foods, diagnostics, medical devices and e-health products. These solutions target conditions ranging from memory impairment to some of the most devastating neurological diseases.
BiotechnologyHealth CareLife ScienceTherapeuticsBiotechnologyBrain healthAlzheimer'sDrug developmentClinical researchKetone therapy
biotechnologybrain healthalzheimersdrug developmentclinical researchketone therapybiotechnology researchb2bketone precursorsfdg pet analogtricaprilinlipid nanoemulsionketone systemneuroprotectioninvestigational drugsketogenic drugs
AWS CloudAmazon Route 53Microsoft Email ProvidersMicrosoft Exchange OnlineOutlookMicrosoft ExchangeMicrosoft 365Microsoft 365 Apps & ServicesAmazon AWSFont AwesomeAdobe FontsGoogle Tag ManagerPriority HintsApache HTTP ServerWordPress.orgCloudflare Rocket LoaderjQueryjQuery Migrate
What the source datasets report. We have not watched these rounds ourselves.
$77M
raised in total across 6 rounds
Last raised Sept 2022, 4 years ago
Who started it and how it trades.
Everything the source datasets list about Cerecin, field by field. Contact details are held but never shown.
The company8 fields
Where4 fields
Size and reach6 fields
Funding, as listed8 fields
Classification4 fields
About this record2 fields
Growth, as the source summarises it
Cerecin may be growing as it has strengthened its position in the neurometabolism market with a new addition to its pipeline. This expansion of its product pipeline indicates an active development phase and potential for increased market share in its sector. The company's focus on neurometabolism, a niche yet significant area within the healthcare industry, suggests a strategic approach to growth by targeting specialized therapeutic areas.
55 Biotechnology companies in Singapore, filtered by size, age and reach, ready to export with emails on Pro.